ERIS Lifescience

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE406M01024
NSEID: ERIS
BSEID: 540596
View on NSE | View on BSE

INR

1,335.65

53.85 (4.2%)

BSENSE

Mar 25

BSE+NSE Vol: 1.37 lacs

{
  "main_header": {
    "sid": 1002771,
    "name": "ERIS Lifescience",
    "stock_name": "ERIS Lifescience",
    "full_name": "ERIS Lifesciences Ltd",
    "name_url": "stocks-analysis/eris-lifescience",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,335.65",
    "chg": 53.85,
    "chgp": "4.2%",
    "dir": 1,
    "prev_price": "1,281.80",
    "mcapval": "18,504.48 Cr",
    "mcap": "Small Cap",
    "scripcode": 540596,
    "symbol": "ERIS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE406M01024",
    "curr_date": "Mar 25",
    "curr_time": "",
    "bse_nse_vol": "1.37 lacs",
    "exc_status": "Active",
    "traded_date": "Mar 25, 2026",
    "traded_date_str": "2026 03 25",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/eris-lifescience-1002771-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Changing Market Sentiment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-changing-market-sentiment-3892663",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ERISLifescience_valuationdot_3892663.png",
        "date": "2026-03-16 08:01:17",
        "description": "ERIS Lifesciences Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the small-cap pharmaceutical player in a new light for investors seeking value within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-3892082",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ERISLifescience_mojoScore_3892082.png",
        "date": "2026-03-15 10:10:23",
        "description": "ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-3881805",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ERISLifescience_valuationdot_3881805.png",
        "date": "2026-03-10 08:01:15",
        "description": "ERIS Lifesciences Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market perceptions and adjustments in key financial ratios such as the price-to-earnings (P/E) and price-to-book value (P/BV) multiples. Investors analysing ERIS Lifesciences must consider these valuation dynamics in the context of its sector peers and historical performance to gauge the stock’s price attractiveness and future potential."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-3868928",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ERISLifescience_mojoScore_3868928.png",
        "date": "2026-03-04 10:10:34",
        "description": "ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "ERIS Lifesciences Declines 5.13%: Margin Pressures and Valuation Shift Weigh on Stock",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-declines-513-margin-pressures-and-valuation-shift-weigh-on-stock-3849535",
        "imagepath": "",
        "date": "2026-02-21 12:03:56",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>16 Feb:</strong> Flat quarterly performance reported amid margin pressures</p>\n                    <p><strong>16 Feb:</strong> Technical downgrade to Sell amid bearish momentum</p>\n                    <p><strong>20 Feb:</strong> Valuation grade shifts from expensive to fair</p>\n                    <p><strong>20 Feb:</strong> Week closes at Rs.1,342.10 (-5.13%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,414.65</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1,342.10</div><div..."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-3849287",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ERISLifescience_mojoScore_3849287.png",
        "date": "2026-02-21 10:10:31",
        "description": "ERIS Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 21 February 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Changing Market Sentiment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-changing-market-sentiment-3847668",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ERISLifescience_valuationdot_3847668.png",
        "date": "2026-02-20 08:01:17",
        "description": "ERIS Lifesciences Ltd has experienced a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade amid a challenging market backdrop. This recalibration reflects evolving investor sentiment and a reassessment of the company’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "ERIS Lifesciences Ltd Faces Bearish Momentum Amid Technical Downgrade",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-faces-bearish-momentum-amid-technical-downgrade-3841697",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ERISLifescience_technicaldot_3841697.png",
        "date": "2026-02-16 08:04:39",
        "description": "ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. The company’s stock price has declined sharply, reflecting deteriorating market sentiment amid a downgrade in its technical grade from Hold to Sell by MarketsMOJO on 9 February 2026."
      },
      {
        "title": "ERIS Lifesciences Reports Flat Quarterly Performance Amid Margin Pressures",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-reports-flat-quarterly-performance-amid-margin-pressures-3841366",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ERISLifescience_fintrenddot_3841366.png",
        "date": "2026-02-16 08:00:47",
        "description": "ERIS Lifesciences Ltd has reported a flat financial performance for the quarter ended December 2025, signalling a notable shift from its previously positive growth trajectory. Despite robust revenue and profit before tax growth, operational challenges such as declining inventory and debtor turnover ratios have weighed on the company’s overall financial health, prompting a downgrade in its Mojo Grade from Hold to Sell."
      }
    ],
    "total": 303,
    "sid": "1002771",
    "stock_news_url": "https://www.marketsmojo.com/news/eris-lifesciences-1002771"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "20-Mar-2026",
      "details": "Launch of generic Semaglutide under the brand SUNDAE in India",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for The Meeting Held Today I.E. March 20 2026",
      "datetime": "20-Mar-2026",
      "details": "As attached",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Directorate",
      "datetime": "14-Mar-2026",
      "details": "Appointment of Mr. Vineet Varma as an Additional Director (Non-executive Independent) of the Company",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "ERIS Lifesciences Ltd has declared <strong>735%</strong> dividend, ex-date: 13 Feb 25",
          "dt": "2025-02-13",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

ERIS Lifesciences Ltd Valuation Shifts Signal Changing Market Sentiment

2026-03-16 08:01:17

ERIS Lifesciences Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the small-cap pharmaceutical player in a new light for investors seeking value within the Pharmaceuticals & Biotechnology sector.

Read full news article

ERIS Lifesciences Ltd is Rated Sell

2026-03-15 10:10:23

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges

2026-03-10 08:01:15

ERIS Lifesciences Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market perceptions and adjustments in key financial ratios such as the price-to-earnings (P/E) and price-to-book value (P/BV) multiples. Investors analysing ERIS Lifesciences must consider these valuation dynamics in the context of its sector peers and historical performance to gauge the stock’s price attractiveness and future potential.

Read full news article

ERIS Lifesciences Ltd is Rated Sell

2026-03-04 10:10:34

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

ERIS Lifesciences Declines 5.13%: Margin Pressures and Valuation Shift Weigh on Stock

2026-02-21 12:03:56

Key Events This Week

16 Feb: Flat quarterly performance reported amid margin pressures

16 Feb: Technical downgrade to Sell amid bearish momentum

20 Feb: Valuation grade shifts from expensive to fair

20 Feb: Week closes at Rs.1,342.10 (-5.13%)

Read full news article

ERIS Lifesciences Ltd is Rated Sell

2026-02-21 10:10:31

ERIS Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 21 February 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

ERIS Lifesciences Ltd Valuation Shifts Signal Changing Market Sentiment

2026-02-20 08:01:17

ERIS Lifesciences Ltd has experienced a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade amid a challenging market backdrop. This recalibration reflects evolving investor sentiment and a reassessment of the company’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

Read full news article

ERIS Lifesciences Ltd Faces Bearish Momentum Amid Technical Downgrade

2026-02-16 08:04:39

ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. The company’s stock price has declined sharply, reflecting deteriorating market sentiment amid a downgrade in its technical grade from Hold to Sell by MarketsMOJO on 9 February 2026.

Read full news article

ERIS Lifesciences Reports Flat Quarterly Performance Amid Margin Pressures

2026-02-16 08:00:47

ERIS Lifesciences Ltd has reported a flat financial performance for the quarter ended December 2025, signalling a notable shift from its previously positive growth trajectory. Despite robust revenue and profit before tax growth, operational challenges such as declining inventory and debtor turnover ratios have weighed on the company’s overall financial health, prompting a downgrade in its Mojo Grade from Hold to Sell.